TheEdgeResearch
Home / Stocks / HROW

Harrow Health, Inc. (HROW)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$40.70 ▲ +0.64%
Market Cap
$1.52B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.26
52-Wk Range
28.54-54.85
CEO
Mark L. Baum
Country
US
Currency
USD

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc.…

Open full interactive analysis & DCF →